Get the Stockscreener App
31.67
1.25%
-0.40
After Hours:
32.29
0.62
+1.96%
Ideaya Biosciences Inc stock is traded at $31.67, with a volume of 810.26K.
It is down -1.25% in the last 24 hours and down -8.99% over the past month.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
See More
Previous Close:
$32.07
Open:
$32.21
24h Volume:
810.26K
Relative Volume:
0.90
Market Cap:
$2.78B
Revenue:
$214.83M
Net Income/Loss:
$-160.74M
P/E Ratio:
-17.07
EPS:
-1.8553
Net Cash Flow:
$-105.39M
1W Performance:
+2.43%
1M Performance:
-8.99%
6M Performance:
+28.17%
1Y Performance:
+51.89%
1-Day Range:
$31.58
$32.95
1-Week Range:
$30.81
$33.31
52-Week Range:
$13.45
$39.28
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Name
Ideaya Biosciences Inc
Sector
Industry
Phone
650-443-6209
Address
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
31.67 | 2.82B | 214.83M | -160.74M | -105.39M | -1.8553 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.05 | 123.82B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.28 | 81.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
816.95 | 52.00B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.36 | 44.14B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
352.23 | 40.83B | 4.98B | 69.60M | 525.67M | 0.5198 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Nov-24-25 | Initiated | Truist | Buy |
| Sep-18-25 | Initiated | Guggenheim | Buy |
| Sep-04-25 | Initiated | Barclays | Overweight |
| Sep-04-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-22-25 | Initiated | TD Cowen | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Jun-26-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Nov-05-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-15-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Mar-08-24 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | SVB Securities | Outperform |
| May-24-23 | Initiated | Goldman | Buy |
| Apr-24-23 | Upgrade | Stifel | Hold → Buy |
| Mar-23-23 | Initiated | Berenberg | Buy |
| Feb-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Dec-28-22 | Initiated | CapitalOne | Overweight |
| Oct-27-22 | Initiated | Citigroup | Buy |
| Aug-15-22 | Downgrade | Stifel | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-10-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Mar-11-21 | Initiated | Guggenheim | Buy |
| Oct-07-20 | Initiated | Wedbush | Outperform |
| Sep-01-20 | Initiated | Northland Capital | Outperform |
| Jul-13-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-06-20 | Initiated | H.C. Wainwright | Buy |
| Mar-13-20 | Initiated | ROTH Capital | Buy |
| Oct-17-19 | Initiated | Oppenheimer | Outperform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Jun-17-19 | Initiated | Citigroup | Buy |
| Jun-17-19 | Initiated | JP Morgan | Neutral |
| Jun-17-19 | Initiated | Jefferies | Buy |
View All
Ideaya Biosciences Inc Stock (IDYA) Latest News
(IDYA) Risk Channels and Responsive Allocation - Stock Traders Daily
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC - The AI Journal
Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of Ide034, A Potential First-In-Class B7h3/Ptk7 Bispecific Top1 Adc - TradingView
Published on: 2026-02-25 12:19:59 - baoquankhu1.vn
Published on: 2026-02-24 09:21:42 - baoquankhu1.vn
IDEAYA Biosciences appoints Theodora Ross as development chief By Investing.com - Investing.com South Africa
IDEAYA Biosciences Teases Late-March Phase III Darovasertib Readout, ADC Updates, New KAT6/7 Phase I Launch - Yahoo Finance
IDYA: Darovasertib's phase 3 PFS readout is imminent, with accelerated approval filing expected this year - TradingView
IDEAYA Biosciences Teases End-of-March Data for Darovasertib Combo at Citi Oncology Summit - Yahoo Finance
Can IDEAYA Biosciences Inc reach all time highs this yearWeekly Stock Analysis & High Accuracy Trade Signal Alerts - baoquankhu1.vn
IDEAYA Biosciences appoints Theodora Ross as development chief - Investing.com
Theodora Ross Joins Ideaya, Leaving Impact on AbbVie (ABBV) - GuruFocus
Ideaya Biosciences Announces Appointment Of Dr. Theodora (Theo) Ross, M.D., Ph.D., As Chief Development Officer - TradingView
AbbVie cancer R&D leader takes charge of IDEAYA’s drug pipeline - Stock Titan
Is IDEAYA Biosciences Inc. forming a breakout patternWeekly Risk Summary & Consistent Growth Equity Picks - mfd.ru
What’s the analyst consensus on IDEAYA Biosciences Inc.Earnings Risk Summary & Weekly Stock Breakout Alerts - mfd.ru
Cantor Fitzgerald reiterates Ideaya Biosciences stock Overweight rating By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Ideaya Biosciences stock Overweight rating - Investing.com
Wedbush Adjusts Price Target on IDEAYA Biosciences to $52 From $49, Maintains Outperform Rating - marketscreener.com
Cantor Fitzgerald Maintains Overweight on IDEAYA (IDYA) Feb 18, 2026 - Meyka
IDEAYA Biosciences, Inc. SEC 10-K Report - TradingView
Published on: 2026-02-17 23:06:22 - mfd.ru
Wedbush Adjusts IDEAYA Biosciences Price Target to $52 From $49, Maintains Outperform Rating - marketscreener.com
Ideaya Biosciences earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update - Finviz
Ideaya Biosciences Q4 Net Loss Narrows as Revenue Rises - marketscreener.com
Earnings Flash (IDYA) IDEAYA Biosciences Posts Q4 Net Loss $0.94 a Share, vs. FactSet Est of $1.05 Loss - marketscreener.com
Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q4 Revenue $10.9M, vs. FactSet Est of $6.3M - marketscreener.com
IDEAYA Biosciences Q4 Loss Declines - Nasdaq
What is IDEAYA Biosciences Inc. s P E ratio telling usJuly 2025 Trends & Verified Swing Trading Watchlists - mfd.ru
(IDYA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Is IDEAYA Biosciences Inc. benefiting from innovation trendsJuly 2025 Price Swings & Weekly Stock Breakout Alerts - mfd.ru
What is IDEAYA Biosciences Inc.’s book value per share2025 EndofYear Setup & Smart Swing Trading Techniques - mfd.ru
IDEAYA Biosciences, Inc. $IDYA Shares Acquired by Candriam S.C.A. - MarketBeat
IDEAYA Biosciences, Inc. (IDYA) Stock Analysis: A 54% Potential Upside in the Precision Medicine Oncology Space - DirectorsTalk Interviews
Citizens reiterates Market Outperform rating on Ideaya Biosciences stock By Investing.com - Investing.com Canada
IDEAYA Biosciences (IDYA): Unpacking The 46.63% Potential Upside In Precision Oncology - DirectorsTalk Interviews
IDEAYA Biosciences, Inc. $IDYA Shares Acquired by New York State Common Retirement Fund - MarketBeat
Liquidity Mapping Around (IDYA) Price Events - Stock Traders Daily
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events - MEXC
Has The Market Overreacted To Recent Weakness In IDEAYA Biosciences (IDYA) Shares? - Yahoo Finance
AlphaQuest LLC Has $1.12 Million Stock Position in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events – Company Announcement - Financial Times
Institution Moves: Is IDEAYA Biosciences Inc benefiting from innovation trends2025 Support & Resistance & Safe Capital Investment Plans - baoquankhu1.vn
A Look At IDEAYA Biosciences (IDYA) Valuation After Recent Share Price Pullback - Yahoo Finance
Knights of Columbus Asset Advisors LLC Invests $934,000 in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GuruFocus
IDEAYA Grants 44,200 Stock Options to New Employee - intellectia.ai
Ideaya Biosciences announces inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
New IDEAYA hire receives 44,200 stock options in Nasdaq inducement grant - stocktitan.net
Forecast Cut: Will IDEAYA Biosciences Inc benefit from geopolitical trendsWatch List & Consistent Income Trade Recommendations - baoquankhu1.vn
Ideaya Biosciences Inc Stock (IDYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.52%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):